Fusion protein modified by klebsiella pneumonia polysaccharide, and application of fusion protein

Abstract

The invention discloses a fusion protein modified by klebsiella pneumonia polysaccharide, and application of the fusion protein. A preparation method for the fusion protein modified by the klebsiellapneumonia polysaccharide comprises the step of expressing the encoding gene of the protein in creatures to obtain the protein modified by the klebsiella pneumonia polysaccharide. The protein is a) orb) or c) or d), wherein a) is the protein formed by an amino acid sequence of SEQ ID No.3, b is the protein formed by an amino acid sequence of SEQ ID No.5, c) is the fusion protein obtained by carrying out protein tag fusion on the carboxyl terminal or / and amino terminal of the protein disclosed by a) or b), and d) is the protein obtained by carrying out substitution and / or deletion and / or addition on the amino acid sequence disclosed by a) or b) through one or multiple amino acid residues.

Description

technical field [0001] The invention relates to a polysaccharide-modified fusion protein of Klebsiella pneumoniae and an application thereof, belonging to the field of biomedicine. Background technique [0002] Klebsiella pneumoniae is a Gram-negative bacterium that is ubiquitous in the environment, on human and animal skin surfaces and mucous membranes. It is an opportunistic pathogen that can cause diseases such as pneumonia, endophthalmitis, bacteremia, and liver abscess. It is easy to infect young children and the elderly and infirm. It has become the most important pathogenic factor of hospital and community-acquired infections. Klebsiella pneumoniae is often drug-resistant, posing enormous difficulties in the treatment of its infection. In addition, the reported cases of Klebsiella pneumoniae capable of producing extended-spectrum β-lactamases have gradually increased in recent years, and clinically there is almost no drug available; in addition, the emergence of high...

AI Technical Summary

Problems solved by technology

The O antigen, especially the O2 antigen, has low immunogenicity. As a vaccine alone, although the safety is well guaranteed, it cannot effectively stimulate the body's immune response, and often requires some adjuvants and suitable delivery systems. to promote the greatest immune response

In recent years, studies have found that nanoscale vaccines often have great application potential and play an important role in enhancing the immunity of weak antigens. Currently, they are widely used in tumor and virus vaccines, but less in the field of bacteria.

[0004] The preparation method of polysaccharide-conjugated vaccines currently on the market is a chemical method. The polysaccharide and protein are activated separately, and then cross-linked by chemical methods.

Since the preparation of the vaccine is completed through chemical reactions, monomeric proteins are often used, and it is difficult to make the vaccine reach the nanoscale

Images